gamma-Aminobutyric acidA receptor regulation by a chloride-dependent kinase and a sodium-dependent phosphatase.
gamma-Aminobutyric acidA (GABAA) receptors are linked to ion channels which mediate many aspects of neural inhibition. Although the effects of phosphorylation on GABAA receptor function have been widely studied, the actual role of phosphorylation in the regulation of these receptors still remains controversial. In recent reports, we have described the effects of phosphorylating/dephosphorylating enzymes on the regulation of GABAA receptors in a rat cortical slice preparation (Shaw et al., Mol. Neuropharmacol., 2 (1992) 297-302; Shaw and Lanius, Dev. Brain Res., 70 (1992) 153-161; Pasqualotto et al., Neuroreport, 4 (1993) 447-450) and predicted that ionic co-factors are involved in mediating the regulation of GABAA receptors by kinases and phosphatases. In the present report, the effects of chloride, sodium, potassium, and calcium were examined alone and in the presence of cAMP-dependent protein kinase (protein kinase A) or alkaline phosphatase. The results showed a decrease in [3H]SR 95531 (GABAA receptor antagonist) binding after incubation with chloride alone; this decrease was further enhanced in the presence of protein kinase A. Both effects could be blocked by a protein kinase A inhibitor. Conversely, an increase in [3H]SR 95531 binding was observed after incubation with sodium alone; this increase was further enhanced in the presence of alkaline phosphatase. In both cases these increases in binding could be blocked by sodium orthovanadate, a phosphatase inhibitor. Potassium was ineffective under all conditions; calcium showed enzyme-independent effects at low concentrations only. These results suggest the existence of a novel chloride-dependent protein kinase which may have significant sequence homology to protein kinase A, and a novel sodium-dependent phosphatase.(ABSTRACT TRUNCATED AT 250 WORDS)
Lanius
R A
RA
Neuroscience Program, University of British Columbia, Vancouver, Canada.
Pasqualotto
B A
BA
Shaw
C A
CA
D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002540:Cerebral Cortex / Q000378:metabolism; D018118:Chloride Channels / Q000502:physiology*; D002712:Chlorides / Q000494:pharmacology / Q000502:physiology*; D018756:GABA Antagonists; D008954:Models, Biological; D010749:Phosphoprotein Phosphatases / Q000502:physiology*; D010766:Phosphorylation / Q000187:drug effects; D011188:Potassium / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000502:physiology*; D011499:Protein Processing, Post-Translational; D011724:Pyridazines / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018079:Receptors, GABA / Q000187:drug effects / Q000502:physiology*; D012964:Sodium / Q000494:pharmacology / Q000502:physiology*
D018118:Chloride Channels; D002712:Chlorides; D018756:GABA Antagonists; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D018079:Receptors, GABA; C049853:gabazine; D012964:Sodium; D011494:Protein Kinases; D010749:Phosphoprotein Phosphatases; D011188:Potassium; D002118:Calcium